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Human beings are members of a whole, 
In creation of one essence and a soul, 
If one member is afflicted with pain, 
Other members uneasy will remain, 
If you’ve no sympathy for human pain, 
The name of human you cannot retain. 
(Saadi 1184-1283) 
 
 
  
 
 
 
 
 
 
 
 
 
To my parents and Yang  
 
 
 
 
 
  
ABSTRACT 
 
Chronic pain is a major concern for physical and mental health of a large patient population 
today while casting a significant economical burden on society. Work presented in this 
thesis deal with aspects of mechanisms and treatments of chronic pain using experimental 
models.  
A common characteristic for many chronic pain conditions, particularly those after nerve 
injury, is hypersensitivity to cold stimulation. In the first part of the thesis, I presented a new 
method using a Peltier thermode to examine the responses of rats to quantitative thermal 
stimulation (heating and cooling). Using this method with temperature as end points, I 
showed that we can reliably detect cold hypersensitivity in spinally injured rats as well as 
study quantitatively the effects of analgesics again cold pain. 
Sinomenine is a morphinan derivative alkaloid originally isolated from the root of the 
climbing plant Sinomenium Acutum that is native to Japan and China. The root of 
Sinomenium Acutum has long been used in East Asia as a remedy for disease conditions 
similar to rheumatism and sinomenine is currently used in China as an anti-rheumatic agent. 
In the second part of the thesis, we characterized the analgesic effect of sinomenine in a 
variety of experimental pain models. We showed that while sinomenine has modest effects 
on acute pain in normal rats, it produces marked analgesic effects in a wide-spectrum of 
models, including neuropathic pain in rats and mice after injury to the peripheral and central 
nervous system, acute inflammatory pain by carrageenan in mice as well as arthritic pain in 
mice using the collagen antibody-induced arthritis model (CAIA). We further showed that 
under chronic administration, sinomenine maintained its analgesic effect in neuropathic and 
arthritic pain models without producing tolerance or dependence. Our results thus suggested 
that sinomenine may be considered as a novel analgesic in treating neuropathic and arthritic 
pain. 
One of the main clinical features of rheumatoid arthritis (RA) is sex difference in its 
prevalence and symptoms, including pain. The underlying mechanisms of sex differences in 
RA are still largely unknown. In the last part of the thesis, we studied sex differences in the 
development arthritis and pain-like behaviors in mice using the CAIA model. We observed 
a significant sex difference (females > males) in the development of joint inflammation and 
localized mechanical allodynia in the paws after CAIA in CBA strain of mice. Similarly, 
female CAIA mice also developed more persistent spread mechanical allodynia in their neck 
and flank areas. Following CAIA, the greater mechanical hypersensitivity in females was 
correlated to a higher expression of ionized calcium-binding adapter molecule 1, but lower 
expressions of activating transcription factor 3 and galanin, in dorsal root ganglion (DRG) 
compared with males.  We conclude that sex differences in the CAIA model in CBA mice 
are similar to the clinical condition and sex dependent phenotypic changes in the DRG may 
be keys for the sex differences in RA and pain. 
 
Key words: Sinomenine, Neuropathic Pain, Sex Difference, Arthritic Pain, Cold Pain, DRG, 
Spinal Cord. 
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1 INTRODUCTION 
 
1.1 PAIN 
 
1.1.1 Definition and classification      
 
Pain is processed by a multilayered system consisting of sensory, cognitive and affective 
components to exert its alarm function (Woolf, 2004). As defined by the International 
Association for the Study of Pain (IASP), pain is an unpleasant sensory and emotional 
experience associated with actual or potential tissue damage (Merskey and Bogduk, 1994). 
Based on the causes, pain can be further classified into three major categories, which are 
nociceptive pain, inflammatory pain and neuropathic pain.  
 
Nociceptive pain is the common discomfort we experienced from noxious stimuli that are, 
or will potentially be, tissue damaging. The nociceptive pain is essential for the survival 
of animals since it serves as a warning signal, which elicits a protective or defensive 
response (Scholz and Woolf, 2002). In most cases nociceptive pain is acute as it stops 
when removing the stimulus. Inflammatory pain is produced by events that associated 
with, for example, tissue injury, infections, burns and autoimmune diseases. Activation of 
localized and recruited inflammatory cells during inflammation results in the release of 
various inflammatory mediators including cytokines, growth factors, neuropeptides, 
kinins, purines, amines, prostanoids and protons (Boddeke, 2001; Manthy et al, 2002) that 
sensitize nociceptors (peripheral receptors respond to noxious stimuli), and increase the 
sensitivity of sensory neurons to noxious stimuli (Scholz and Woolf, 2002).  
Inflammatory pain can be both acute and chronic. Neuropathic pain is pain following a 
primary lesion or dysfunction in the peripheral or central nervous system (Merskey and 
Bogduk, 1994). In the majority of the cases, neuropathic pain is chronic, difficult to 
manage and associated with plastic changes in the nervous system (Hökfelt et al., 1994).  
 
1.1.2 Noxious stimuli and pain transmission 
 
The sensation of pain starts from the detection of noxious (mechanical, thermal or 
chemical) stimulus by peripheral nociceptors in the skin (Basbaum and Jessell, 2000). 
Nociceptors are sensitive nerve terminals, consisting of two main categories which are Aδ 
mechanical and C-polymodal (Meyer et al, 2008). Aδ fibers are thinly myelinated 
afferents that giving rise to sharp, pricking pain to mechanical or thermal stimulation at 
high intensity. C fibers are unmyelinated afferents with small diameters and lower 
conduction velocity, that responding to both mechanical and thermal stimuli at various 
intensities (D’Mello and Dickenson, 2008). Noxious stimuli are converted into electrical 
activities by nociceptors (Scholz and Woolf, 2002), and then transmitted into spinal cord 
via dorsal root ganglion (DRG) neurons, which synapse onto the dorsal horn neurons 
(Besson and Chaouch, 1987; Basbaum et al, 2009).  
 
The primary afferents terminate in the dorsal part of the spinal cord following a highly 
organized style. Aδ fibers and C fibers predominately terminate in the superficial laminae 
I and II (Light and Perl, 1979), while large myelinated fibers such as Aα and Aβ fibers 
usually terminate more ventrally in laminae III and IV (Brown, 1981; Besson and 
Chaouch, 1987). Dorsal horn neurons responding to peripheral stimulation are generally 
classified into three types: low threshold neurons preferably activated by innocuous 
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stimuli, wide dynamic range (WDR) neurons, responding to a range of stimulation 
coming from thermal, chemical and mechanical modalities in a graded pattern with 
respect to the intensity of stimulation, and high threshold neurons that respond exclusively 
to noxious stimuli (Cervero et al, 1976; Besson and Chaouch, 1987).  
 
When nociceptive inputs have been transmitted to the dorsal horn, signals are integrated 
at the spinal level and generated, often through specific interneuron mediated networks, 
local somatic or sympathetic reflexes. The nociceptive signal will also be further relayed 
to the medulla, brainstem and thalamus via ascending tracts. The thalamus is the region 
where pain inputs are integrated, through which, pain signals are forwarded to cortical and 
sub-cortical brain regions, mainly to somatosensory cortex for the surveillance of pain, 
and limbic system for the affective components of pain (Bester et al., 2000; Tracey, 
2005). Also, the midbrain periaqueductal gray (PAG) and the rostral ventral medulla 
(RVM) are involved in pain modulation by either inhibiting or facilitating the spinal 
nociceptive input (Porreca et al, 2002).  
 
1.1.3 Thermal pain 
 
Physiological studies showed that human subjects feel cold pain below 15°C and heat 
pain at above 47°C (Morin and Bushnell, 1998), suggesting that there are cutaneous 
nociceptors that responding to noxious thermal stimulation. The cell membrane of these 
primary afferent fibers expresses receptors known as transient receptor potential (TRP) 
ion channels that  are specified for converting thermal and chemical stimuli into electrical 
signals (Pertovaara, 2013).  
 
 
 
Fig. 1 Thermal TRP channels, their temperature responding ranges, and activation profile 
by chemicals. 
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Mammalian TRP channels that are expressed in sensory nerve endings are characterized 
by their distinctive temperature-dependent activation patterns (Fig. 1). There are two TRP 
channels expressed in sensory neurons for the perception of cold, namely TRPA1 and 
TRPM8. TRPA1 is activated by noxious cold temperatures below 17°C, while TRPM8 
responds to gentle cooling with an activation threshold of about 25°C. TRPV4 and 
TRPV3 are activated by warmer temperatures, above 25°C and 33°C respectively. 
TRPV1 and TRPV2 are activated by noxious heat with respective thresholds of 42°C and 
52°C (Belvisi et al., 2011). All TRP channels can also be activated by various chemicals 
present in the environment (Fig.1).  
 
Of the TRP channels expressed on nociceptive nerve fibers, the best known are TRPA1 
and TRPV1. TRPA1 is activated by various irritant compounds such as mustard oil and 
icillin (Fig. 1), as well as noxious mechanical stimulation (Patapoutian et al., 2009). 
TRPA1 deletion in mice resulted in deficits in behavioral responses to noxious cold, 
assessed using the cold plate (0°C), and acetone tests (Kwan et al., 2006). TRPV1 is 
activated by painful heat and chemicals such as capsaicin (Fig. 1). However, studies have 
shown that the cold activated current was blocked by high dose of TRPV1 antagonist 
capsazepine (Foulkes and Wood, 2007), indicating there is also a potential role played by 
TRPV1 in cold pain transduction.  
 
Unlike TRPA1 and TRPV1, which are predominately expressed in nociceptive nerve 
endings, TRPM8 is expressed in 5-10% of the DRG neurons with both non-nociceptive 
and nociceptive nerve fibers (Mckemy et al., 2002). Genomic knockout of TRPM8 
produced a marked reduction of the response to topical acetone, which is a cold stimulus 
in mice without affecting noxious cold senses (Colburn et al., 2007). Neurons that 
responding to innocuous cool and noxious cold are found in lamina I of the spinal cord 
and trigeminal dorsal  horn and have been shown to project to the thalamus in the brain 
(Dostrovsky and Craig, 1996). Stimulation of TRPM8 might be able to modulate pain 
since it could potentially activate a subpopulation of the presumed spinal pain–relay 
neurons (Pertovaara, 2013). 
 
1.2 CHRONIC NEUROPATHIC AND RHEUMATOID ARTHRITIS PAIN 
 
1.2.1 Neuropathic pain 
 
In the European Union the prevalence of chronic pain is around 20% in adults and 
imposes a huge burden on society (Breivik et al., 2006). Neuropathic pain accounts for 
most of the worst clinical chronic pain situations and disabilities caused by chronic 
neuropathic pain significantly decreases the quality of life not only in the patients 
themselves but also in their care-giving family members (Ebrahimzadeh et al., 2013). 
Neuropathic pain can be classified into peripheral or central neuropathic pain depending 
on the location of primary lesion (Jensen et al., 2001) or categorized according to the 
etiological diagnosis, for example painful diabetic neuropathy, trigeminal neuralgia, 
postherpetic neuralgia, and posttraumatic neuralgia.  
 
The major symptoms of neuropathic pain are spontaneous pain, allodynia, hyperalgesia 
and the loss of sensory functions (Jensen et al., 2001; Baron et al, 2010). Allodynia is 
abnormal pain perception by stimulations that generally do not cause any tissue damage. 
Mechanical allodynia is thought to be mediated by the low threshold Aβ fibers. Therefore, 
gentle brushing of the skin can evoke intense pain sensations in neuropathic pain patients 
(Jensen et al., 2001). In contrary, hyperalgesia is a term used to describe the exaggerated 
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response to a noxious stimulus. Spontaneous pain in neuropathic pain is stimulus-
independent, and can be either continuous or paroxysmal. It is usually described as 
shooting, electric shock-like, burning or stabbing. Partial or complete loss of afferent 
sensory function is another essential consequence in neuropathic pain conditions, leading 
to sensory deficit in these patients (Jensen et al., 2001).  
 
The mechanisms of neuropathic pain have been extensively studied. It is generally 
believed that complex changes in the peripheral and central nervous system that related to 
sensory pathways are initiated following peripheral injury. Damaged afferents become the 
source of abnormal neuronal activation, arising either from the injured axon or the cell 
body in the DRG (Wall and Devor, 1983). The ongoing inputs from these afferents 
subsequently induce hypersensitivity in dorsal horn neurons, a process sometimes known 
as central sensitization (Woolf, 1983). Activation of trans-membrane G coupled N-
Methyl-D-aspartate (NMDA) receptors in the spinal cord is one of the key component in 
central sensitization (Woolf, 1983). Another central change that is known to occur in 
neuropathic pain states is the deficiency in inhibitory mechanisms, in particular, loss of 
gamma-aminobutyric acid (GABA)-ergic and glycinergic neuronal transmissions (Castro-
Lopes et al., 1993). Finally, nerve injury produced marked plasticity alterations in the 
DRG and central nervous system (CNS), including expression changes of ion channels 
and neuropeptides in sensory neurons, which are related to the development of 
neuropathic pain (Hökfelt et al., 1994).  
 
1.2.2 Pain in Rheumatoid Arthritis 
 
Chronic pain is one of major symptoms in rheumatoid arthritis (RA), and the primary 
reason for RA patients to seek medical care. There are several factors impacting RA pain 
in human. For instance, women usually have higher pain ratings than men (Wolfe and 
Michaud, 2007). Furthermore, RA pain is most common between 50 and 62 years of age, 
which may be related to changes in physical activity (Wolfe and Michaud, 2007). In the 
joints all structures with the exception of cartilage are innervated by nociceptors. In RA, 
the auto-immune reaction elicits physical and biochemical changes leading to local 
secretion of inflammatory mediators including prostaglandins and cytokines. These 
inflammatory mediators sensitize nociceptors in the joints, resulting in the perception of 
evoked pain during movement and spontaneous pain during the resting state (Bas et al., 
2012). In addition to acute pain experienced during disease flares, more than 40% of the 
RA patients also develop chronic pain within 5 years after the disease onset (Andersson et 
al., 2013). The prevalence of spread pain symptoms such as fibromyalgia is also higher 
among the patients with RA than in general population (Lee, 2013).  
 
Clinical experience suggests that in RA patients there is poor correlation of pain 
symptoms and the peripheral inflammation. The treatment of inflammatory incidences in 
disease flares of RA has been markedly improved since the introduction of biologic drugs. 
These therapies can successfully halt the progression of inflammation by blocking the 
effect of cytokines, T cells and B cells. However, despite the improvements in disease 
control, pain, particularly chronic pain, is still a problem in many RA patients (Wolfe and 
Michaud, 2007; Andersson et al. 2013).  
 
1.2.3 Animal models of chronic pain 
 
The application of clinically relevant animal models is of paramount importance in 
studies of the mechanisms and treatments of chronic pain. In neuropathic pain research, 
the development of the chronic nerve constriction model by Bennett and Xie (1988) was 
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an important milestone as they showed that it is possible to produce a partial injury to the 
sciatic nerve, enabling the observed behaviors of animals to be similar as human 
conditions of hyperalgesia and allodynia. Since then, a large number of models has been 
developed using a variety of methods to induce injury in different nerves. These models 
have greatly facilitated the experimental research on neuropathic pain (Xu and 
Wiesenfeld-Hallin, 2003).  
 
Our laboratory has been using a photochemical technique to produce ischemic injury to 
the spinal cord and peripheral nerves. This method involves intravascular interaction 
between a photosensitizing dye and a laser beam at the appropriate wavelength, leading to 
the generation of singlet oxygen radicals at the endothelial cells of capillaries and 
subsequent platelet aggregation within the blood vessels in the irradiated nervous tissues 
(Watson et al., 1986; Kupers et al., 1998). Our laboratory developed one of the first spinal 
cord injury (SCI) pain models using this method (Xu et al., 1992). Thus, after spinal 
ischemic injury rats developed marked pain-like behaviors to mechanical and cold 
stimulation in the dermatomes corresponding to injured spinal segments in a manner that 
is similar to SCI patients (Hao et al. 1991, 1992, Xu et al. 1992, 1994). This model has 
been used to test the efficacy of a large number of anagesics against central pain. The 
photochemical technique has also been used in producing partial sciatic nerve injury in 
rats and mice (Kupers et al. 1998; Hao et al. 2002) and infraorbital nerve injury in rats 
(Eriksson et al., 2005). Some of these models are used in the present work to test the 
effect of analgesics. 
 
Several rodent models of RA have been developed based on pathophysiological 
mechanisms of the disease. One of the early models is the adjuvant arthritis (AA) model 
in rats which involves injecting Freund’s complete adjuvant into susceptible strains of rats 
resulting in a T cell-mediated autoimmune arthritis. Another widely used model is the 
collagen-induced arthritis (CIA) model in which autoimmune arthritis is produced in 
some strains of mice by immunization with an emulsion of complete Freund's adjuvant 
and type II collagen (CII). In the present thesis, we have utilized the collagen antibody-
induced arthritis (CAIA) model, which is a novel mouse model of RA, based on the 
injection of a cocktail of monoclonal antibodies targeted against type II collagen 
following by lipopolysaccharide (LPS) immunization (Nandakumar and Holmdahl, 
2007). In this model, the local joint pathology resembles that observed in RA patients, and 
there is a development of robust pain-like behaviors (Bas et al., 2012). Important 
advantages of the CAIA model include: (i) good overall health for the affected mice, (ii) 
shortened disease duration as it does not depend on breakage of tolerance and bypasses 
the natural development of anti-collagen antibodies and (iii) the fact that it can be 
generated in many strains of mice that are resistant to CIA (Nandakumar and Holmdahl, 
2007).  
 
1.3 SEX DIFFERENCES 
 
1.3.1 Sex differences in pain 
 
As an important modulator for the perception of pain, sex has been increasingly 
recognized and studied by the international pain research community. It has been 
recognized that there is a sex difference in pain sensitivity. Females generally have lower 
pain threshold and tolerance than males (Berkley, 1997; Fillingim et al, 1999; Mogil, 
2000; Barrett et al, 2002; Wiesenfeld-Hallin, 2005; Greenspan et al, 2007). In addition, 
women also experience more variable pain episodes, which usually last longer than in 
men with similar conditions (Berkley, 1997; Hurley and Adams, 2008). These 
 6 
differences, however, are small, exist only for certain forms of stimulation modalities and 
are affected by many factors such as the presence of disease and experimental setting 
(Berkley 1997). A large number of chronic pain conditions, e.g. migraine, 
temporomandibular disorder (TMD), RA, irritable bowel syndrome (IBS), and 
fibromyalgia are more common in women (Ektor-Andersen et al, 1993; Whitacre, 2001; 
Craft et al, 2004; Holdcroft and Berkley, 2005; Greenspan et al, 2007). The response to 
analgesics has also been reported to be sex dependent. For example, morphine appears to 
have a stronger analgesic effect in males than in females (Berkley 1997; Mogil, 2000).  
 
Estrogen exerts its effects via interaction with receptors which belong to a super family of 
nuclear receptors. Activation of estrogen receptors (ERs) in the nucleus induces an 
estrogen response element, leading to modulation of transcription of estrogen-regulated 
genes. Two forms of ERs have been identified, namely ERα and ERβ (Gruber et al, 2002; 
Koehler et al, 2005). Previous studies have shown that both ERα and ERβ are presented in 
the CNS and also expressed in DRG neurons (Papka and Storey-Workley, 2002), 
suggesting their potential role in sensory modulation. In our lab, we have shown that 
either knocking out ERα or ERβ can render female mice responding to pain more like 
males with increased basal pain threshold and a higher resistance to carrageenan induced 
inflammatory pain (Li et al., 2009).  
 
1.3.2 Sex differences in Rheumatoid Arthritis 
 
Basic immune responses differ between females and males, i.e. following immunization, 
female mice produce more antibody and show more vigorous T cell activation than male 
mice. Women have higher absolute numbers of cluster of differentiation (CD) 4
+   
lymphocytes in comparison to men, which may contribute to their increased immune 
responses (Whitacre, 2001). One of the important clinical features of RA is the higher 
incidence of occurrence in women. A large number of epidemiological studies have 
shown that, in general, the sex ratio (women vs. men) of RA is typically at about 3:1, and 
women usually have higher pain ratings during the disease than men (Whitacre, 2001; 
Wolfe and Michaud, 2007).  
 
Changes in levels of circulating gonadal hormones have been implicated to be one of the 
main causes for the overrepresentation of women in RA and RA associated chronic pain. 
Pregnancy appears to protect against the development of RA and ameliorate RA 
symptoms with most profound effect during the third trimester, when estrogen and 
progesterone concentrations reach their peak (Whitacre, 2001), which is reversed shortly 
post partum. In contrast, the incidence of RA in women peaks after menopause where the 
reduction in estrogen level has been shown to facilitate ongoing pain in RA and also in 
TMD and migraine (LeResche et al, 1997; Brandes, 2006). Interestingly, men who 
develop RA have significantly lowered testosterone levels compared with healthy subjects 
(Whitacre, 2001), indicating that the sex hormones estrogen, progesterone and 
testosterone can modulate RA disease activity. 
 
In animal models of RA the role of sex has been unclear. Experimental studies of CIA 
have shown that in some mouse strains there was a reversed sex difference compared with 
the clinical situation in that male mice displayed a higher incidence of arthritis than 
females (Holmdahl et al., 1989; Jansson et al., 1994). Ovariectomy (OVX) or blockade of 
estrogen receptors in these females appears to increase the incidence and severity of 
arthritis whereas treatment with estradiol suppresses symptoms in ovarietomized female 
mice (Jansson et al., 1994). However, whether such pattern of sex difference is also true 
   7 
for other preclinical models of RA generated in other strains, and with regard to RA 
induced arthritic pain, remains to be further examined.  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
1.4 ANALGESICS 
 
1.4.1 Analgesics in neuropathic pain 
 
Neuropathic pain is difficult to treat using available pharmacological agents. The non-
steroidal anti-inflammatory drugs (NSAIDs), which are the most commonly used pain 
medicines worldwide, have no effect in neuropathic pain. Opiates, the ultimate class of 
strong analgesic, have at best ambiguous effects against neuropathic pain in the majority 
of patients (Arnér et al., 1998). Opiates also produce significant side effects, including 
respiratory depression, constipation and long term administration is associated with 
tolerance, dependence and abuse. 
 
The first line of analgesics prescribed today to treat neuropathic pain is gabapentin and 
pregabalin (Attal et al. 2010). Gabapentin and pregabalin are structurally related to 
GABA, but their effects appear not to be mediated by the GABAergic system. Instead, 
they interact with the α2δ subunit of the voltage-dependent L-type calcium channel in the 
CNS, suppressing neuronal excitability and decreasing the release of neurotransmitters. 
The clinical indication for gabapentin and/or pregabalin in neuropathic pain include 
diabetic neuropathy, post-herpetic neuralgia, central pain and fibromyalgia, but evidence 
indicate that these drugs can only achieve partial relief of pain in patients (Serpell, 2002; 
Gordh et al., 2008).  
 
Another class of analgesics that may be potentially used in neuropathic pain are 
antagonists of the NMDA receptors, particularly those of non-competitive and low 
affinity nature such as dextromethorphan (Hao and Xu, 1996). However, despite strong 
pre-clinical results, there is still a lack of convincing clinical evidence for analgesic effect 
of this type of drugs in neuropathic pain. 
 
1.4.2 Analgesics in arthritic pain 
 
Disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate are known to 
reduce acute symptoms in RA including pain, but their efficacy against the development 
of chronic pain is less clear (Taylor et al., 2010; Andersson et al., 2013; Steiman et al., 
2013). In early RA patients, treatments with NSAIDs, acetaminophen, biological drugs or 
sometimes weak opioids have been shown to be effective in reducing acute inflammatory 
pain (Strand et al., 2012, Lee et al. 2013). However, these drugs appear to have limited 
effects against chronic pain in the absence of joint inflammation (Whittle et al., 2012; 
Andersson et al., 2013; Lee et al. 2013). Long term application of these drugs are however 
limited by side effects and in the case of opioids, the development of tolerance (Lang et 
al., 2010).  
 
1.4.3 Sinomenine 
 
Botanicals, compounds extracted from plants, have contributed significantly to our 
arsenal of pharmacological treatment of diseases. The discovery of artemisinin for 
treating malaria is probably the best example of a successful development of a novel drug 
from Chinese herbal medicine, a feat that will likely be repeated many times in the future.  
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Sinomenine is a morphinan derivative alkaloid that is structurally similar to 
dextromethorphan (Fig. 2), found in the root of the climbing plant Sinomenium Acutum 
which is native to Japan and China. Sinomenine has long been used in East Asia as a 
remedy for disease conditions similar to rheumatism as recorded in the 16
th
 century book, 
Bencao Gangmu (Compendium of Materia Medica). It is still clinically used in China 
and Japan for conditions such as RA, arrhythmia and neuralgia (Yamasaki, 1976). In 
mice, treatment with sinomenine decreased the incidence and severity of arthritis in the 
CIA model (Huang et al., 2007). Compared with NSAIDs, sinomenine was more effective 
in the reduction of morning stiffness, painful joints and erythrocyte sedimentation rate in 
RA patients (Xu et al., 2008). Clinical studies also demonstrated that sinomenine may be 
effective in relieving pain in RA and some types of neuralgia, such as sciatic neuritis, 
lumbalgia and muscular rheumatism (Yamasaki, 1976).  
 
Fig. 2 Chemical Structure of Sinomenine 
Receptor binding studies have shown that sinomenine is able to activate the opioid µ 
receptor in vivo at high concentrations and long-term pretreatment with sinmenine may 
delay the onset of morphine analgesic tolerance (Wang et al., 2008). In addition, 
sinomenine can downregulate the elevated levels of cyclic adenosine monophosphate 
(cAMP), 5-hydroxytryptamine (5-HT), noradrenaline, dopamine, and neuronal nitric 
oxide synthase (nNOS) in the cerebral cortex (Wang et al., 2002 and 2003), to maintain 
a normal state in morphine-dependent, naloxone-precipitated withdraw rats. 
Furthermore, SIN exhibited anxiolytic-like effect that resembling the effect of the 
partial 5-HT1A agonist Gepirone (Chen et al., 2005). 
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2. AIMS OF THE THESIS 
 
The general aims of the thesis are to use experimental methods to study the mechanisms 
and treatments of chronic pain.  
 
 
In particular:  
 
1. To develop a method to quantitatively examine pain-like responses to thermal 
(heat and cold) stimulation in spinally injured rats.  
 
2. To validate CAIA as a model of arthritic pain. 
 
3. To study the potential analgesic of sinomenine in acute nociceptive pain and in 
chronic neuropathic and arthritic pain models. 
 
4. To study sex difference in the development of arthritis and pain in the CAIA 
model and to explore the mechanisms of sex differences. 
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3. MATERIALS AND METHODS  
 
3.1. ANIMALS 
 
All experiments were approved by regional animal research ethics committee and were 
carried out according to the Ethical Guidelines of IASP. Sprague-Dawley (SD) rats of 
both sexes (Harlan, Horst, The Netherlands; Möllegård, Denmark), male C57BL/6 mice 
(Charles River, Sollentuna, Sweden), and CBA mice of both sexes including females 
which were ovarectomized at 20 days of age at the facility of the animal provider (Harlan, 
Horst, The Netherlands) were used. Animals were housed 4 per cage for rats and 6 per 
cage for mice at a constant room temperature of 22°C in a 12:12h light-dark cycle with ad 
libitum access to food and water. 
 
3.2. INFLAMMATORY PAIN MODELS  
 
3.2.1 Collagen antibody induced arthritis model 
 
As described previously (Bas et al., 2012) , CAIA was induced in mice by intravenous 
(i.v.) injection of anti-CII arthritogenic cocktail (0.15 ml, Chondrex, USA) containing 5 
monoclonal antibodies at day 0, followed by intraperitoneal (i.p.) injection of 35 µg LPS 
(serotype O55:B5; Sigma) in 100 µl of physiologic saline on day 5. Control groups 
received 100 l of saline i.v. on day 0. On day 5, the saline control group received i.p. 
saline, while the LPS control group received i.p. LPS. Inflammation in the joints was 
evaluated by visual inspection and scored every third day after injection of the antibody 
cocktail. The scoring was based on the number of inflamed joints in each paw, 
inflammation being defined by swelling and redness (Nandakumar and Holmdahl, 2007). 
Briefly, each inflamed toe or knuckle gave one point, an inflamed wrist or ankle gave five 
points, resulting between 0 and 60 points for each mouse. 
 
3.2.2 Carrageenan-induced inflammation in mice 
 
Mice were anaesthetized with 75 mg/kg ketamine + 1 mg/kg medetomidine in a volume 
of 1 ml/kg, and λ-carrageenan (Sigma-Aldrich, 20 µl, 2%) was injected subcutaneously 
(s.c.) into the plantar surface of one hind paw. Mechanical and heat threshold of the 
inflamed hind paw was tested 24h after the injection.   
 
3.3. NERVE INJURY MODELS 
 
3.3.1 Photochemically induced sciatic nerve injury in mice and rats 
 
Detailed methods for producing sciatic nerve ischemic injury (SNI) have been described 
previously for rats (Kupers et al., 1998) and mice (Hao et al., 2002). Briefly, animals were 
anaesthetized by 75 mg/kg ketamine + 1 mg/kg medetomidine and the left sciatic nerve 
was exposed. After i.v. injection of the photosensitizing dye erythrosine B (Red N°3, 
Aldrich-Chemie, Steinheim, Germany) at the dose of 32.5 mg/kg, sciatic nerve was 
irradiated under an argon ion laser (514 nm, 160 mW, Innova model 70, Coherent Laser 
Product Division, Palo Alto, CA) for 45 s or 2 min for mice or rats, respectively.  
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3.3.2 Photochemically induced spinal cord injury in rats 
 
Photochemically induced spinal cord ischemic injury method has been described 
previously (Hao et al., 1992). Briefly, the rats were anaesthetized with 75 mg/kg ketamine 
+ 1 mg/kg medetomidine in 1 ml/kg and one jugular vein was cannulated. A midline 
incision was made in the skin overlying vertebral segments T12-L1. The animals were 
positioned beneath the argon laser beam and irradiated for 10 min with the beam directed 
towards vertebral segment T12 or T13 (spinal segments L3-5). Immediately prior to and 5 
min after the start of the irradiation, erythrosin B (Red N°3, Aldrich-Chemie, Steinheim, 
Germany) dissolved in 0.9% saline was injected i.v. at a dose of 32.5 mg/kg. During 
irradiation, the body temperature of the rats was maintained at 37-38°C. 
 
3.4. BEHAVIORAL TESTS  
 
3.4.1 Hot plate test in rats  
 
The antinociceptive effect of Sinomenine in normal rats was assessed using a hot plate 
(IITC, Woodland Hills, CA) which was maintained at 54 °C ± 1 °C. The latency to lick a 
hind paw was measured with an accuracy of 0.1 s and the cut-off value was set at 30 s to 
prevent tissue damage. Before testing, the rats were habituated in the testing room for at 
least 30 min. The rats were trained on the hot plate for 4 days with 2 trials/day to obtain a 
stable baseline response prior to the experiment.  
 
3.4.2 Tail flick test in mice and rats 
 
In the tail flick test the mice or rats were gently restrained and a radiant heat source (Ugo 
Basile, Italy) was focused 1 to 2 cm from the tip of the tail. Response latency was 
automatically recorded. The intensity of the stimulation was adjusted so that the baseline 
latency was from 4 to 6 s and the cut-off value was 10 s 
 
3.4.3 Paw withdrawal threshold to mechanical stimulation in rats and mice 
 
The withdrawal threshold of the ipsilateral hind paw to mechanical stimulation after 
sciatic nerve injury in rats was tested using a set of calibrated von Fray hairs (Stoelting, 
Chicago, IL, USA). Briefly, rats were placed in plastic cages with a metal mesh floor. 
After habituation for 1 h, the plantar surface of the ipsilateral hind paw was stimulated 
with increasing force. Each filament was applied 5 times and response threshold was 
reached when the animal withdrew the paw at least 3 times. The cut-off value was 60 g. 
The hind paw withdraw threshold to mechanical stimulation in mice with sciatic nerve 
injury or carrageenan-induced inflammation was tested using the same set of calibrated 
von Fray hairs (Stoelting, Chicago, IL, USA) in a way similar to that in rats except that 
the cut-off value was 4 g. 
 
In CAIA mice, control baselines were measured five times every third day before the 
collagen antibody injection. Animals with baseline threshold below 50% of the average 
value were excluded from the experiment. Mechanical threshold was tested every third 
day for 54 days at the same time during the day. For testing of the paw withdrawal 
threshold mice were randomly placed in plastic cages with a metal mesh floor. After 
habituation for one hour, the plantar surface of the hind paw was stimulated with a set of 
calibrated von Frey hairs (Marstock, Denmark), using the up-down method (Chaplan et 
al., 1994) to calculate the force that caused paw withdrawal in 50% of trials. For testing 
forepaw withdrawal threshold another set of von Frey hairs (Stoelting, Chicago, IL, USA) 
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was used. Stimuli were applied 4 to 8 times to the plantar surface of the forepaw with the 
frequency of 1/s at each force. The stimulus which induced consistent withdrawal (>75% 
respond rate) was considered as forepaw withdrawal threshold.  
 
3.4.4 Assessment of spread mechanical allodynia in spinally injured rats and CAIA 
mice 
 
Sensitivity to mechanical stimulation in SCI rats was tested by examining the vocalization 
thresholds to graded mechanical touch/pressure applied with calibrated von Frey hairs 
(Stoelting, Chicago, IL, USA). During testing the rats were gently restrained in a standing 
position and the von Frey hair was pushed onto the skin until the filament became bent. 
The frequency of the stimulation was about 1/s and 5 to 10 stimuli were applied at each 
force. The intensity of stimulation which induced consistent vocalization (>75% response 
rate) was considered as pain threshold. For testing spread mechanical hypersensitivity in 
CAIA, mice were gently restrained in a standing position. The flanks and upper back were 
stimulated using the same set of von Frey hairs. Stimuli were applied 5 to 10 times with 
frequency of 1/s, at each force. The intensity which induced consistent vocalization 
(>60% respond rate) was considered as vocalization threshold. The cut-off value was 
100g on the flanks and back. 
 
3.4.5 Thermal stimulation using a Peltier thermode in SCI rats 
 
The Peltier effect is an end-to-end transfer of heat when electric current is passed in a 
circuit consisting of two dissimilar semiconductors that result in cooling off one junction 
while heating up the other. The surface temperature of a Peltier thermode can be 
maintained or adjusted by varying the current. The development and application of a 
Peltier thermo stimulator in rats has been described previously (Wilcox et al., 1984). In 
this study, a fluid cooled, hand held Peltier thermode (active surface: 25 x 50 mm, control 
resolution: >0.02 °C, calibration uncertainty: +/- 0.2 °C) connected to a Modular Sensory 
Analyzer (MSA) Thermal Stimulator (Somedic, Sweden) was used for thermal 
stimulation. The baseline temperature was 32°C and the rate of temperature change was 
0.5°C/s. Rats were held gently in a standing position and the thermode was pressed 
against the shaved flank area. Three heating stimuli were applied at 1 min intervals and 
the average temperature at which the rats vocalized was taken as heat response threshold 
with 50°C as cut-off temperature.  Similarly, three cooling stimuli were then applied at 1 
min intervals and the average temperature at which the rats vocalized was taken as cold 
response threshold with 6°C as cut-off temperature. 
 
3.4.6 Measurement of cold hypersensitivity using ethyl chloride spray 
 
SCI rats were gently restrained in a standing position and ethyl chloride spray (Rönnings 
Europa AB, Sweden) was applied to the shaved allodynic flank area. The response was 
graded with a score of 0 = no observable response; 1 = localized response (skin twitch and 
contraction), no vocalization; 2 = transient vocalization, moderate avoidance and 3 = 
sustained vocalization and avoidance. For SNI rats and mice, the immediate response 
after acetone application on the hind paw was observed and scored for both mice and rats 
as follows: 0= no responses; 1= startle response without evident paw withdrawal, 2 = 
withdraw of the stimulated hind paw, 3 = sustained withdraw of the simulated hind paw 
with flitching or licking.  
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3.4.7 Test of heat hyperalgesia in mice with carrageenan-induced inflammatory 
pain 
For test of heat hyperalgesia, mice were gently restrained and a radiant heat source (Ugo 
Basile, Italy) was focused on the plantar surface of the hind paw. The intensity of the 
stimulation was adjusted so that the baseline latency was from 4 to 6 s and the cut-off 
value was set at 10 s. 
3.4.8 Tactile response test 
 
For examining the response to brush stimuli, the skin on the flanks was briskly stroked 
with the point of a pencil in a rostral to caudal direction. The response of the animals was 
graded with a score of 0 = no response, 1 = moderate efforts to avoid the probe but no 
vocalization, 2 = clear avoiding behavior to the stimulus with transient vocalization, and 3 
= vigorous efforts to avoid the stimulus, sustained vocalization in response to the probe.  
 
 
3.4.9 Motor tests 
We have used a combined motor tests of walking in an open field and a righting reflex to 
detect the potential motor and sedative effect of sinomenine in spinally injured rats which 
are most prone to motor and sedative effect of drugs (Table 1). 
Grade Description Score 
Walking 
0 Normal walking 0 
1 Walks with only mild deficit 5 
2 Walks with deficit, hind limb can support weight  15 
3 Frequent movement of hind limb, no weight bearing 25 
4 Minor movement in hind limb, no weight bearing 40 
5 No movement of hind limb, no weight bearing 45 
Righting  
0 Normal righting counter to the direction of roll 0 
1 Weakened attempt of righting  5 
2 Delayed attempt of righting  10 
3 No attempt of righting  15 
Table 2. Combined motor score of rats 
3.5. IMMUNOHISTOCHEMICAL STUDY 
 
Animals were deeply anesthetized with sodium pentobarbital (Mebumal; 50 mg/kg, i.p.) 
and transcardially perfused with 20 ml warm saline (0.9%, 37°C), followed by 20 ml of 
warm picric acid-paraformaldehyde (PFA) fixative solution (4% PFA with 0.2% picric 
acid in 0.16 M phosphate buffer, pH 7.35, 37°C), and then 50 ml of the same fixative at 
4°C. The L4 and L5 DRGs as well as the L4 and L5 segments of the spinal cord were 
dissected out and post fixed in the same fixative for 3h at 4°C, and subsequently 
transferred to 20% sucrose in phosphate-buffered saline (PBS; pH7.4) containing 0.01% 
sodium azide (Sigma) and 0,02% bacitracin (sigma) at 4°C for 2 days. Tissues were 
embedded with OCT compound (Tissue Tek, Miles Laboratories, Elkhart, Ind., USA), 
frozen and cut in a cryostat (Microm, Heidelberg, Germany) at 12μm (DRGs) or 20μm 
(spinal cords). For single “TSA plus” staining, mounted sections were dried at RT for 30 
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min and incubated with primary antibodies against ATF-3 (Santa Cruz, rabbit, catalogue 
#sc-188,1:4,000), GAP-43 (Chemicon, rabbit, catalogue #AB5220, 1:1,000), Iba-1 
(WAKO, rabbit, catalogue #019-19741, 1:2,000), GFAP(DAKO, rabbit, catalogue 
#Z0334, 1:8,000), galanin (rabbit, 1:4,000; Theodorsson and Rugarn, 2000), SP (rabbit, 
1:4,000; Christensson-Nylander et al., 1986), CGRP (rabbit, 1:32,000; Orazzo et al., 
1993), CD68 (Abcam rabbit, catalogue #AB125212, 1:2000) overnight at 4°C in a humid 
chamber. Immunoreactivity was visualized using the tyramide signal amplification system 
(Perkin Elmer, USA). Briefly, the slides were rinsed with TNT buffer (0.1M Tris–HCl, 
pH 7.4; 0.15 M NaCl; 0.05% Tween 20) for 15 min, blocked with TNB buffer (0.1M 
Tris–HCl; pH 7.4; 0.15M NaCl; 0.5% blocking reagent (Perkin Elmer, Boston, MA) for 
30 min, followed by a 30-min incubation with secondary antibody diluted in TNB buffer. 
After a quick wash (15 min) in TNT buffer, all sections were exposed to biotinyl 
tyramide-fluorescein (1:100) diluted in amplification diluent for 10 to 15 min (all steps at 
RT). For double staining, CD68 was stained using tyramide signal amplification, while 
Iba-1 primary antibody was incubated with secondary antibody (Invitrogen, goat anti 
rabbit, catalogue #A11037, 1:200) at the following day. DRG Sections were 
counterstained for 15 min with 0.001% (w/v) propidium iodide (PI, Sigma) in PBS, and 
all slides were coverslipped with anti-fading mounting medium (DABCOTM, Sigma).  
 
Images were captured by a 710 LSM system (Zeiss, Jena, Germany) and operated by 
LSM ZEN2009 software (Zeiss). Multi-panel figures were assembled in Adobe 
Photoshop CS5 software (Adobe Systems Inc., San Jose, CA). Quantification in DRG 
staining was done by using the percentage of positive neurons over all neurons (for 
galanin, ATF-3, GAP-43, SP and CGRP), and the number of positive cells colocalized 
with PI in a randomly selected region (232µm 232µm, for Iba-1). In spinal cord 
stainings, signal intensity of markers expressed in the dorsal horn region was measured 
and normalized with background value.      
 
3.6. QPCR STUDY 
 
On days 15 and 54 following the induction of CAIA, lumbar spinal cords and L4 and L5 
DRGs were dissected and immediately frozen at -80°C. Before qPCR analysis, mRNA 
was extracted using TRIzol (Invitrogen), and complementary DNA was produced. As to 
determine relative mRNA levels, quantitative real-time PCR was performed with TaqMan 
Gene Expression Assays (Applied Biosystems), using the GeneAmp 7500 Fast Sequence 
Detection system (Applied Biosystems). Pre-developed specific primers were used to 
detect HPRT1 (reference gene, TaqMan, Mm00446968_m1), galanin (TaqMan, 
Mm01236508_m1), ATF-3 (TaqMan, Mm00476032_m1) and GAP-43 (TaqMan, 
Mm00500404_m1) signals. Sample threshold cycle values in standard curve samples 
(mouse RAW 264.7 cells stimulated with LPS for 4h and standard spinal cord or DRG 
tissues from CAIA mice) were used to calculate the cDNA concentration equivalents in 
the DRG and spinal cord samples, and then the data were normalized to HPRT gene 
expression to obtain relative concentrations and presented as relative expression units.   
 
3.7. DRUGS  
 
For preparation of injecting solutions, sinomenine (standard substance was obtained from 
The National Institute for Food and Drug Control, Beijing, China) was firstly dissolved 
with DMSO (Sigma-Aldrich), then mixed with Cremophor EL oil (Sigma-Aldrich) and 
saline by a vortex mixer (Bibby Scientific, UK) using the volume rate of 1:4:5. Any 
further dilution was made with saline. The opioid receptor antagonist naloxone was 
obtained from Tocris (Bristol, UK) and dissolved in saline. For single dose application, 
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sinomenine was administered i.p., s.c., or p.o. in rats and mice. To perform oral 
administration, the rat/mouse was held in an upright standing position and a bulb tipped 
gastric gavage needle was used to deliver the sinomenine solution into the stomach by the 
attached syringe. For chronic administration, sinomenine was administered twice daily for 
5 days at 10:00 h and 16:00 h.  
 
3.8. STATISTICS 
 
Statistics were performed using Statview software (SAS Institute Inc., USA). The 
experiments were conducted blindly. Data were presented as mean  ±  error of the mean 
(SEM) or median  ±  median absolute deviation (MAD), and were analyzed with analysis 
of variance (ANOVA) with/without repeated measurements or the Kruskal–Wallis test, 
followed by Bonferroni/Dunn’s test, Fisher’s Protected Least Significant Difference 
(PLSD) test, Dunnett’s test, Wilcoxon signed rank test, and paired t-test. For unpaired 
comparisons, the Mann-Whitney U test and unpaired t test were used. Simple linear 
regression analysis was performed and the significance of correlation was tested by 
ANOVA. For all the statistics, p<0.05 was considered as significant.  
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4. RESULTS 
 
4.1. QUANTITATIVE TEST OF RESPONSES TO THERMAL STIMULATION IN 
SPINALLY INJURED RATS (PAPER I) 
 
4.1.1. The development of mechanical and cold hypersensitivity in spinally injured 
rats 
 
The vocalization threshold to stimulation with von Frey hairs in normal rats was 60 -100g. 
Photochemically induced SCI produced marked mechanical hypersensitivity in the 
majority of rats starting at day 1 with vocalization threshold of 2-6 g, which was 
maintained for at least 70 days (Fig. 2a, Paper I).  Mechanical allodynia was present on 
the flank and lower back areas corresponding to the dermatome of injured spinal 
segments. In the same area, cold stimulation with ethyl chloride spray triggered pain-like 
response in SCI allodynic, but not normal rats (Fig. 2b, Paper I). Such cold allodynia 
could be detected 1 day after injury and was maintained for the 70 days of observation 
period (Fig. 2b, Paper I). A sub-population of rats (10-20 %), however, did not exhibit 
mechanical hypersensitivity after SCI (non-allodynic rats). 
 
4.1.2. Quantitative thermal testing in spinally injured rats 
 
Normal rats had no aversive response to cooling by a Peltier thermode from 32°C to 6°C 
on the flank area. The vocalization threshold of SCI rats was increased significantly from 
day 1 (Fig. 3a, Paper I), and lasted for at least 70 days (Fig. 3a, Paper I). The cold 
hypersensitivity was prominent in the first two weeks and almost all rats demonstrated a 
cold pain threshold above 17°C immediately after injury. Towards the end of the 10 week 
observation, around 50 % of rats still had consistent vocalization threshold above 17°C.  
 
The majority of normal rats did not exhibit pain-like response to warm/heat stimulation up 
to 50°C, with few responses between 47-50°C. The heat response temperature was not 
significantly decreased in SCI rats throughout the whole observation period (Fig. 3b, 
Paper I). 
 
4.1.3. Correlation analysis of cold response temperature with cold scores and 
mechanical response threshold 
 
Using simple linear regression we found that in the same allodynic rats the cold response 
temperature was highly correlated with the cold response score in individual rats (r
2
 
=0.612, p<0.01) (Fig 4a, Paper I). Furthermore, there was also a significant, albeit less 
robust, correlation between vocalization threshold to mechanical stimulation and cold 
response temperature (r
2
 =0.231, p<0.01) in these rats (Fig. 4b, Paper I). 
 
4.1.4. Cold responses in non-allodynic spinally injured rats 
 
A sub-population of rats did not develop mechanical allodynia after spinal cord injury 
(non-allodynic rats with mechanical threshold >15g). No significant increase in cold 
response to ethyl chloride was observed in non-allodynic rats compared with controls  
(Fig. 5a, Paper I). However, when tested with the Peltier thermode and using response 
temperature as endpoint, we observed that the non-allodynic rats were hypersensitive to 
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cold and they differed significantly from both the control group and allodynic group (Fig. 
5b, Paper I). 
 
4.2. WIDE-SPECTRUM ANALGESIC EFFECT OF SINOMENINE IN RODENTS 
AFTER INFLAMMATION AND NERVE INJURY (PAPER II) 
 
4.2.1. Antinociceptive effect of sinomenine in hot plate and tail flick tests 
 
Systemic sinomenine produced antinociception in the hot plate and tail flick tests in male 
rats (Paper II, Fig.1A, B) at 40 mg/kg, but not at lower doses (10 or 20 mg/kg). The effect 
was significant at 30 min in the hot plate test (Paper II, Fig.1A) and at 30, 60 and 90 min 
in the tail flick test (Paper II, Fig.1B). At 10-40 mg/kg sinomenine did not produce any 
observable side effect such as sedation, allergy or motor impairments. At 80 mg/kg, 
sinomenine had a moderate sedative effect. Antinociception was also seen in mice at 60 
min following 80 mg/kg i.p. sinomenine, but not at lower doses (20 or 40 mg/kg) in the 
tail flick test (Paper II, Fig. 1C). Sinomenine at 80 mg/kg i.p. did not produce any 
observable side effects in mice. Vehicle had no effect. 
 
4.2.2. The effect of sinomenine on carrageenan-induced mechanical and heat 
hypersensitivity 
 
Carrageenan injected s.c. into the plantar surface of hind paws of male mice induced 
mechanical and heat hypersensitivity at 24 h post injection, which were significantly 
reduced by sinomenine administered orally (p.o.) in mice at 80 mg/kg (but not at lower 
doses) for up to 120-180 min (Paper II, Fig. 2A, B). Sinomenine at 80 mg/kg p.o. did not 
produce any observable side effects in mice. 
 
4.2.3. The effect of sinomenine on mechanical and cold hypersensitivity after 
peripheral nerve injury in mice and rats 
 
The effect of sinomenine was tested 2 weeks after sciatic nerve injury, when the animals 
exhibited mechanical and cold hypersensitivity of the hind paws. I.p. sinomenine at 40 
mg/kg reversed mechanical and cold hypersensitivity in rats (Paper II, Fig. 3A, B). 
Mechanical and cold hypersensitivity was also present in mice after sciatic nerve injury. 
I.p or p.o. sinomenine at 40 or 80 mg/kg dose dependently reduced mechanical 
hypersensitivity in nerve injured mice (Paper II, Figs. 4A, 5A). Interestingly, sinomenine 
did not reduce cold hypersensitivity following either i.p. or p.o. administration in mice 
(Paper II, Fig. 4B, 5B). The effect of 80 mg/kg i.p. sinomenine on mechanical 
hypersensitivity in nerve injured mice was not reversed by i.p. naxolone (1 mg/kg, 60 min 
after sinomenine) (Paper II, Fig. 6). 
 
4.2.4. The effect of sinomenine on mechanical and cold hypersensitivity in spinally 
injured rats 
 
The pharmacological experiments were conducted in female SD rats 4-5 weeks after the 
induction of spinal cord injury when the animals exhibited hypersensitivity to innocuous 
mechanical and cold stimulation at the flank area at or just rostral to the dermatome of  
the injured spinal segments (Xu et al., 1992). I.p. sinomenine at 40 mg/kg, but not lower 
doses or vehicle, significantly decreased mechanical and cold allodynia for up to 240 min 
(Paper II, Fig. 7 A, B) without producing any observable side effects. 
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4.3. REPEATED SINOMENINE ADMINISTRATION ALLEVIATES CHRONIC 
NEUROPATHIC PAIN-LIKE BEHAVIORS IN RODENTS WITHOUT 
PRODUCING TOLERANCE (PAPER III) 
 
4.3.1. Effect of repeated administration of sinomenine on pain-like behaviors in 
spinally injured rats 
 
Sinomenine dose-dependently suppressed hypersensitivity to mechanical (Paper III, Fig 
1) and cold (Paper III, Fig 3) stimulation in rats after spinal cord injury. Saline had no 
effect on either mechanical (Paper III, Fig 1A, 2A) or cold (Paper III, Fig 3A) responses. 
A single dose of i.p. sinomenine at 10 or 20 mg/kg had no effect on responses to 
mechanical or cold stimulation in SCI rats (Paper III, Fig 1-3) as previously reported 
(Paper I).  
 
In contrast, repeated administration of 10 mg/kg sinomenine twice per day elevated 
vocalization threshold to mechanical stimulations and reduced response score to brushing 
from day 2 to day 5 of treatment (Papper III, Fig 1B, 2B). However, repeated 
administration of 10 mg/kg sinomenine had no effect on hypersensitivity to cold (Paper 
III, Fig 3B). Repeated administration of sinomenine at 20 mg/kg reduced mechanical 
hypersensitivity to stimulation with von Frey hairs and brushing from day 2 to day 5 
(Paper III, Fig 1C, 2C). Furthermore, pre-drug response threshold to von Frey hairs was 
significantly elevated from day 2 of sinomenine treatment and the threshold remained 
significantly elevated compared to day 1 for at least 4 days after the cessation of drug 
application (Paper III, Fig 1C).  The pretreatment response score to brushing was also 
significantly decreased from day 4 to day 6 after the start of drug treatment (Paper III, Fig 
2C). However, 20mg/kg sinomenine did not alleviate allodynia to cooling (Paper III, Fig 
3C).  
 
Sinomenine administered 2/day at 40 mg/kg effectively reduced mechanical 
hypersensitivity. Baseline thresholds to stimulation with von Frey hairs was significantly 
increased from day 2 of treatment and lasted until day 9, 4 days after the last 
administration of sinomenine (Paper III, Fig 1D). The response threshold returned to pre-
drug baseline level on day 12 (Paper III, Fig 1D). Hypersensitivity to brushing was also 
reversed on days 2, 4 and 5 following repeated Sinomenine (Paper III, Fig 2D). The 
threshold temperature for cold stimulation was significantly decreased (indicating a 
decrease in cold hypersensitivity) 2h after sinomenine during the first two days (Paper III, 
Fig 3D). The pre-drug cold response temperature was significantly reduced from baseline 
level from day 2 to day 9 (Paper III, Fig 3D), again suggesting a sustained reduction in 
cold hypersensitivity.  
 
4.3.2. Effect of repeated sinomenine on neuropathic pain-like behaviors in mice 
following sciatic nerve injury 
 
Saline had no effect on paw withdrawal threshold (Paper III, Fig 4A) or cold sensitivity 
(Paper III, Fig 4C). Sinomenine at 80 mg/kg administered p.o. twice a day for 5 days 
produced significantly increased paw withdrawal threshold on days 1 to 5 (Paper III, Fig. 
4B). There was also a significant and persistent elevation in pre-drug baseline response 
threshold to simulation with von Frey hairs from day 2 and was maintained for 7 days 
after the termination of drug treatment (Paper III, Fig. 4B). Sinomenine also significantly 
reduced mechanical and cold post-drug responses, in comparison with the pre-drug 
thresholds (Paper III, Fig 4B, D). 
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4.4. SINOMENINE ALLEVIATES MECHANICAL HYPERSENSITIVITY IN 
MICE WITH EXPERIMENTALLY-INDUCED RHEUMATOID ARTHRITIS 
(CAIA)  (PAPER IV) 
 
4.4.1. The dose-dependent effect of sinomenine against mechanical hypersensitivity 
of the hind paw in mice with CAIA 
 
During the inflammatory phase of CAIA (days 11-19 after CII antibody injection), a 
single dose of 40 and 80 mg/kg s.c. Sinomenine dose-dependently reduced mechanical 
hypersensitivity in the hind paws (Paper IV, Fig. 1A). In the post-inflammatory phase 
during days 35-54 post CII antibody, sinomenine also had a similar effect as during peak 
inflammation (Paper IV, Fig. 1B). No side effects such as sedation or motor impairments 
were observed following sinomenine administration. 
 
4.4.2. The dose-dependent effect of sinomenine against spread mechanical 
hypersensitivity  
 
Mice subjected to CAIA developed, in addition to localized mechanical hypersensitivity 
of the paws, a spread mechanical hypersensitivity primarily at the neck and flanks (Paper 
V). A single dose of 40 or 80 mg/kg sinomenine also significantly alleviated the spread 
mechanical hypersensitivity during both the inflammatory and post-inflammatory phases 
of CAIA (Paper IV, Fig 2A, B).  
 
4.4.3. Effect of repeated administration of sinomenine 
 
Repeated injection of 80 mg/kg sinomenine 2 times/day for 5 days during days 11-15 post 
CII antibody administration (inflammatory phase), had no effect on the arthritic scores in 
mice with CAIA in comparison to saline treated animals (Paper IV, Fig. 3A). Sinomenine 
administered 2/day for 5 days during the peak of inflammation significantly alleviated the 
mechanical hypersensitivities in the hind paws (Paper IV, Fig. 3B) and in the neck/flank 
region (Paper IV, Fig. 3C). Baseline mechanical hypersensitivity was significantly 
increased from the second day after the start of repeated sinomenine treatment, and 
remained significantly elevated for 3 days after the cessation of sinomenine treatment 
(Paper IV, Fig. 3B, C). During the post inflammatory phase, repeated sinomenine 
administration (at days 49-53 post CII antibody administration, 80 mg/kg, 2/day) 
significantly alleviated mechanical hypersensitivity both of the hind paws and on the 
neck/back regions (Paper IV, Fig. 3A, B). Baseline mechanical hypersensitivity was 
significantly increased from the second day after the onset of repeated sinomenine 
treatment for the hind paw, but only on day 5 for the spread hypersensitivity (Paper IV, 
Fig. 3B, C). The effect persisted for at least one day after the cessation of sinomenine 
treatment as the experiments were terminated on day 54 according to a pre-determined 
schedule (Paper IV, Fig. 3B, C). No side effects were observed during repeated 
sinomenine treatments during both the inflammatory and post-inflammatory phases. 
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4.5. SEX DIFFERENCES IN THE DEVELOPMENT OF ARTHRITIS AND PAIN 
IN MICE WITH COLLAGEN ANTIBODY-INDUCED ARTHRITIS (PAPER 
V) 
 
4.5.1 Joint inflammation and effect of ovariectomy after CAIA 
 
Both male and female CBA mice developed joint inflammation (measured with the 
Arthritis Score) after the induction of CAIA (Paper V, Fig. 1A). Female mice had 
significantly higher arthritis score than males for forepaws and hind paws over the entire 
observation period. The female mice had both higher peak and longer duration of joint 
inflammation as judged by the arthritis scores (Paper V, Fig. 1A). The extent of joint 
inflammation was also significantly more severe in the forepaws compared to the hind 
paws, particularly for the male mice (Paper V, Fig. 1A, B). Ovariectomized (OVXd) 
female mice resembled males in the development of joint inflammation following CAIA 
(Paper V, Fig. 1C). There were significant overall differences between males and females 
and between females and OVXd females, but not between males and OVXd females as 
analyzed using area under the curve (Paper V, Fig. 1C, D).  
 
4.5.2 Development of mechanical hypersensitivity after CAIA and the effects of 
ovariectomy 
 
Both male and female CBA mice developed mechanical hypersensitivities in hind paws 
after induction of CAIA, not seen in the saline control groups (Paper V, Fig 2A). Female 
mice had a significantly lower response threshold to mechanical stimulation than males 
during the whole 54 day observation period (Paper V, Fig. 2A, B). OVXd female mice 
also developed significant, mechanical hypersensitivity in the hind paws following CAIA, 
but not after saline treatment (Paper V, Fig. 2A). The magnitude of mechanical 
hypersensitivity in CAIA-treated OVXd females was between female mice and male 
mice, so that there were no significant overall differences between OVXd females and 
females or between OVXd females and males (Paper V, Fig. 2A, B). Mechanical 
hypersensitivity was also detected in the forepaws (Paper 5, Fig 2C, D) and in the neck 
and upper back region as illustrated in both male and female mice after CAIA (Paper V, 
Fig 2E, F). There were also significant sex differences in spread mechanical 
hypersensitivity between male and female mice (Paper V, Fig 2E, F). 
 
4.5.3 Expression of Substance P and CGRP in lumbar DRGs and spinal cord 
dorsal horn 
 
For substance P (SP) and calcitonin gene related peptide (CGRP), the expressing profiles 
were similar among male and female as well as OVXd mice in the DRG of saline treated 
groups (around 15 % and 35 % positive neuronal profile in the DRG for SP and CGRP 
respectively, Paper V, Fig 3A, B, C). The level of SP or CGRP expression were not 
altered in the DRGs in the CAIA groups on day 15 or day 54 after induction of 
inflammation (Paper V, Fig 3A, B). The level of SP or CGRP expression was also similar 
in the dorsal horn among three groups of mice studied and, again, CAIA did not alter the 
expression pattern of SP or CGRP in the dorsal horn (Paper V, Fig 4A, B, C). 
 
4.5.4 The expression of ATF-3 and GAP-43 in lumbar DRGs  
 
The qPCR analysis revealed equal increases in activating transcription factor 3 (ATF-3) 
mRNA levels in male and female DRGs 15 days (inflammatory phase), but not 54 days 
(post-inflammatory phase), after CAIA-induction (Paper V, Fig 5A). The number of 
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ATF-3 positive DRG neuron profiles (NPs) was significantly increased in male, female 
and OVXd female mice 15 days after CAIA-induction (Paper V, Fig 6A, D). On day 54, 
only male and OVXd female mice had significantly elevated ATF-3 NPs (Fig 6A). There 
was a marked sex difference in ATF-3 positive DRG NPs at both time points (male > 
female). Similar to ATF-3, growth associated protein 43 (GAP-43) mRNA levels were 
only increased on day 15 in male and female CAIA mice (Paper V, Fig 5B). There was a 
general increase in immunohistochemical staining of GAP-43 in lumbar DRGs in LPS 
control groups (day 15) and CAIA groups in comparison to the saline control groups 
(Paper V, Fig 6B, D), which reached statistical significance for CAIA male, female and 
OVXd mice on days 15 and 54 (Paper V, Fig 6B). No significant sex differences in 
mRNA or positive NPs for GAP-43 were detected at both time points (Paper V, Fig 5B, 
6B). 
 
4.5.5 Expression of galanin in lumbar DRGs and spinal cord dorsal horn  
 
We have conducted qPCR analysis of galanin transcript levels in DRGs in male and 
female mice after saline injection or CAIA induction. On day 15 after CAIA, the levels of 
galanin mRNA was significantly elevated in male but not female DRGs (Paper V, Fig 
5C). Only few galanin-positive NPs were observed in the lumbar DRGs in the saline 
treated mice with no differences among the three groups, males, females and OVXd 
females (Paper V, Fig 6C, D). Induction of CAIA significantly increased the number of 
galanin-positive NPs in all three groups on day 15 and day 54 (Paper V, Fig 6C, D). There 
was also a significant sex difference between male and female mice at both time points 
with males having significantly higher number of galanin-positive NPs (Paper V, Fig 6C). 
OVX partially reversed such sex difference (Paper V, Fig 6C). Galanin expression was 
not significantly affected by CAIA induction in comparison to saline group in both male 
and female spinal dorsal horns (Paper V, Fig 7A, C). A small, but significant, sex 
difference (male > female) was recorded (Paper V, Fig 7A).  
 
4.5.6 Expression of GFAP and Iba-1 in spinal cord dorsal horn and lumbar DRGs 
 
The intensity of glial fibrillary acidic protein (GFAP) staining in the dorsal horn was 
significantly increased after CAIA at day 54, but not on day 15 in both male and female 
mice (Paper V, Fig 7B, C). There was no sex difference in the intensity of GFAP staining 
after CAIA. Induction of CII Abs and LPS also induced upregulation of the number of 
cell profiles positive for Iba-1 staining in the lumber DRG on days 15 and 54 after 
induction of inflammation in both male and female mice (Paper V, Fig 8A, C). There was 
a significant sex difference on day 15 (female > male) for the number of Iba-1 positive 
cells in the DRGs, which was however not affected by ovariectomy (Paper V, Fig 8A). 
Iba-1 positive and CD68 positive cells were colocalized  in the DRGs (Paper V, Fig 8D). 
In CAIA mice there was also an increased intensity of staining for Iba-1 in the dorsal horn 
in both male and female mice on day 15, but only in female mice on day 54 (Paper V, Fig 
8B, C).  
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5. DISCUSSION 
 
 
5.1. QUANTITATIVE THERMO TESTING IN RATS WITH SPINAL CORD 
INJURY 
 
We showed that a Peltier thermode, which is used in quantitative sensory testing in 
humans, can also be effectively used for quantitative assessment of thermal response 
threshold in rats with SCI.  Thus, we can determine the response threshold temperature 
for heating and cooling in normal rats and detect the presence of cold allodynia in SCI 
rats as the temperature required to elicit pain-like response was significantly increased 
following SCI. The SCI rats did not exhibit increased response to heat stimulation in the 
same area where mechanical and cold allodynia were observed. These results are similar 
to clinical findings in patients with SCI, who had hypersensitivity to mechanical and cold, 
but not to heat stimulation (Finnerup et al., 2003). Lack of heat hyperalgesia has also been 
reported in several other clinical studies in this patient population (Eide et al., 1996; 
Defrin et al., 2001).  
 
Recent studies of the TRP family of ion channels have identified two TRP channels, 
TRPM8 and TRPA1, as the primary targets for sensing cool and noxious cold with 
activation threshold below 28°C and 17°C, respectively (McKemy et al., 2002 and 2005; 
Story et al., 2003; Stucky et al., 2009). Since quantitative measurement of cold allodynia 
in the present study indicated that around 50% of rats showed consistent vocalization 
threshold above 17°C, which is generally believed to only activate TRPM8 receptors 
(Foulkes and Wood, 2007; Stucky et al., 2009), it is likely that activation of TRPM8 cold 
receptors is involved in mediating cold allodynia in spinally injured rats. We have 
previously reported that treatment of spinally injured rats with a high dose of 
resiniferatoxin (RTX), which produces a substantial desensitization of capsaicin-sensitive 
afferents, abolished cold allodynia (Hao et al., 1996). Interestingly, a sub-population of 
capsaicin sensitive afferents expresses TRPM8 receptors where they coexist with TRPV1 
channels (McKemy et al., 2002; Stucky et al., 2009). 
 
A strong positive correlation was found between cold response temperature tested with 
the Peltier thermode and cold response score tested with ethyl chloride spray. Thus, rats 
that showed stronger response to a supra-threshold cold stimulation also had higher 
temperature threshold to cooling (Hao et al., 1996 and 1998; Kouya et al., 2002). A less 
robust, but significant correlation was found between the response to cold and mechanical 
threshold. We have shown that mechanical allodynia in SCI rats, was not affected by 
RTX treatment (Hao et al., 1996). However, we recently found that mechanical allodynia 
in spinally injured rat is enhanced by topical application of the cold mimetic icilin or 
menthol (Gao et al., 2013b). Therefore, although the afferents mediating mechanical and 
cold allodynia may be different in the spinal cord injured rats as judged by their 
sensitivity to RTX treatment (Hao et al., 1996), it is likely that there are common central 
mechanisms responsible for the increased responsiveness to mechanical and cold 
stimulation.  
 
The quantitative method for assessing response temperature increased the reproducibility 
and sensitivity of the cold test in SCI rats compared to cold scores following stimulation 
with ethyl chloride. This may be particularly important for future pharmacological 
experiments. The increased sensitivity of the test can already be seen from current results, 
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where a sub-population of spinally injured rats that did not develop mechanical allodynia 
(Xu et al., 1994; Hao et al. 1998; Endo et al. 2008). We have previously reported that 
these non-allodynic rats did not have cold hypersensitivity as tested with ethyl chloride 
spray (Hao et al., 1998). However, the present results showed that these rats are 
hypersensitive to cold compared to normal rats (although less so than allodynic rat), an 
effect that was not detectable with the cold spray method.  
 
5.2. THE WIDE SPECTRUM ANALGESIC EFFECT OF SINOMENINE 
 
We showed in papers II-IV that a single systemic administration of sinomenine produced 
antinociception in several rodent models of acute and chronic pain, including against 
acute heat pain in normal rats, mechanical and heat hypersensitivity in mice subjected to 
short term inflammation by carrageenan, localized and spread mechanical hypersensitivity 
in CAIA arthritic mice, mechanical and cold hypersensitivity in mice/rats after sciatic 
nerve injury and mechanical and cold hypersensitivity in SCI rats. The doses of 
sinomenine in these studies (up to 80 mg/kg) are in line or lower than those used in 
previous studies in rodents, mostly for studies on its effects against arthritis (Liu et al. 
1996; Huang et al., 2007). Only at the highest i.p. dose of sinomenine, 80 mg/kg, did we 
observe a mild sedative effect in rats whereas antinociception was observed at 40 mg/kg. 
No side effects were seen in mice at any dose. Together, the consistent effect of 
sinomenine across a wide spectrum of models and the lack of interfering side effects 
suggest that sinomenine is antinociceptive and/or analgesic in rodents. 
 
The analgesic effect of sinomenine has not been well studied before despite some 
anecdotal clinical evidence for its effects against pain in sciatic neuritis, lumbalgia and 
muscular rheumatism (Yamasaki, 1976). Wang et al. (2008) showed that in mice 30 
mg/kg systemic sinomenine produced moderate antinociception in the tail flick test in 
mice which agrees with our results in normal rodents. Sinomenine appears to be most 
effective against pathological pain after inflammation, and particularly, nerve injury. 
Thus, the profile of analgesia produced by sinomenine is different from that of systemic 
morphine in our models of nociceptive pain vs. neuropathic pain (Bulka et al., 2002; Yu 
et al. 1997). The effect of sinomenine may, however, be similar to the effect of 
dextromethorphan, a non-opioid antitussive that is an NMDA receptor antagonist, which 
was effective against allodynia after spinal cord injury (Hao and Xu, 1996) while having 
limited effect in normal rats. It is interesting to note that sinomenine is structurally related 
to levorphanol and dextromethorphan and while there is currently no evidence that 
sinomenine can function as an NMDA receptor antagonist, it does have a neuroprotective 
effect possibly mediated by blocking of acid-sensing ion channel and calcium channels 
(Wu et al. 2011).  
 
The anti-allodynia effect of sinomenine was not reversed by naloxone at a dose that 
blocks the three main subtypes of opioid receptors (Handal et al., 1983), suggesting that 
the effect of sinomenine against neuropathic pain is non-opioid in nature. It has been 
previous shown that sinomenine can bind to or activate the µ-opioid receptor at high 
concentration in vitro and the weak anti-nociceptive effect of sinomenine in mice hot 
plate test can be blocked by naloxone (Wang et al., 2008). We did not examine the effect 
of naloxone against sinomenine in normal rodents and it is possible that the involvement 
of opioid receptors is different for the effect of sinomenine between normal and 
neuropathic states.  
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5.3. REPEATED SINOMENINE ADMINISTRATION ALLEVIATES CHRONIC 
NEUROPATHIC PAIN WITHOUT TOLERANCE 
 
We showed that repeated administration of sinomenine produced no signs of tolerance. 
Furthermore, we observed a significant increase in pre-drug response threshold after two 
injections, and this effect was maintained for 7 days after the termination of drug 
administration in SCI rats. In both rats and mice, sinomenine appears to be less effective 
against cold than mechanical hypersensitivity, which is similar to our previous results 
(Gao et al., 2013). In addition, no side effects (sedation, motor impairment or irritation) 
were observed during or after repeated sinomenine administration. Previous studies in rats 
have also suggested that daily administration of sinomenine at 40 or 80 mg/kg for two 
weeks did not influence growth, appetite and blood pressure (Zhu, 1998). There were also 
no apparent withdrawal symptoms following the termination of drug treatment in the 
present study. These observations, together with the fact that no tolerance to the anti-
allodynic effects of sinomenine was observed after repeated administration, suggest that 
sinomenine may be useful to treat chronic neuropathic pain.  
 
The effects of repeated administration of sinomenine on neuropathic pain-like behaviors 
in our models are similar to the effect of the anti-epileptics lacosamide and gabapentin 
(Hao et al., 2000 and 2006; Wu et al., 2004). In particular, the analgesic effect of 
gabapentin was also increased following repeated administration at doses that were 
ineffective as a single injection (Hao et al., 2000). Moreover, repeated lacosamide 
alleviated predrug baseline responses, similar to that of sinomenine (Hao et al., 2006). In 
contrast, i.p. morphine did not alleviate allodynia in rats with SCI, whereas i.t. morphine 
did have some anti-allodynic effect, but tolerance was observed after 2 days of twice daily 
treatment (Yu et al., 1997b). One of the remarkable effects of sinomenine in these two 
rodent models of neuropathic pain is that it reduced baseline hypersensitivity following 
repeated administration, resulting in persistent reduction in allodynia. Since sinomenine 
has a relatively short half-life in rat plasma (Liu et al., 1996; Ling et al., 2005), it is 
unlikely that this effect is due to an accumulation of the drug following repeated 
injections. Some of the anti-allodynic effects of sinomenine may be mediated by its 
metabolites which are known to be present in at least three forms (Cheng et al., 2007). 
However, it is unknown whether these metabolites are pharmacologically active. 
Alternatively, the effects of repeated sinomenine administration may reflect sustained 
physiological changes resulting from repeated drug treatment. Such changes are, 
however, reversible and may require continuous drug treatment since allodynia recurred 
within days following the last dose of sinomenine. 
 
The mechanism of action for the anti-allodynic effect of sinomenine in models of 
neuropathic pain is not clear. As mentioned above the anti-allodynic effect of sinomenine 
was not reversed by the opioid receptor antagonist naloxone (paper II) and the profile of 
analgesia produced by sinomenine is different from that of systemic morphine (Bulka et 
al., 2002; Yu et al., 1997 and 1997b). In contrast, the effect profile of sinomenine is 
similar to that of dextromethorphan, a non-opioid antitussive which is a weak 
noncompetitive NMDA receptor antagonist (Hao and Xu, 1996). In accordance, we found 
repeated administration of sinomenine delayed tolerance to morphine (Wang et al., 2002; 
Wang et al., 2003), which was also observed with dextromethorphan (Elliott, 1994). One 
of the possible mechanisms for the anti-allodynic effect of chronic sinomenine may be 
related to its ability to modulate neurotransmitter release in the spinal cord and brain. 
Systemic sinomenine alters the level of monoamines in extracellular fluid in the striatum 
in rats after sciatic nerve injury with increase in the level of noradrenaline and decrease in 
   25 
level of dopamine and serotonin (Zhang et al., 2013). These effects are correlated with 
analgesic effect of sinomenine (Zhang et al., 2013). Chronic SIN may produce long term 
effects on transmitter synthesis and neuronal functions through altered transmitter release. 
Sinomenine also has distinct immunoregulatory and neuroprotective properties. It can 
reduce the production of cyclooxygenase  (COX)-2 dependent prostaglandin E2 (PGE2) 
(Liu et al., 1994), as well as block nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κB) and p38 mitogen-activated protein kinases (p38MAPK) signal pathways 
(Wang et al., 2005; Huang et al., 2008). It is conceivable that some of these properties 
may reduce neuronal sensitization contribute to sinomenine’s analgesic effects in 
neuropathic pain. 
 
5.4. THE EFFECT OF SINOMENINE ON EXPERIMENTAL RHEUMATOID 
ARTHRITIS  
 
Sinomenine is used in China and Japan as an anti-rheumatic drug (Yamasaki, 1976). The 
efficacy of sinonemine against RA is well established in rodent RA models (Liu et al. 
1996; Huang et al. 2007). Clinically, sinomenine was more effective than NSAIDs in 
ameliorating morning stiffness, painful joints and erythrocyte sedimentation rate in RA 
patients (Xu et al., 2008). The mechanism of the effect for sinomenine against RA has 
been suggested to be due to its ability to reduce the production of proinflammatory 
cytokines by suppressing the activation of NF-κB (Wang et al., 2005; Zhou et al., 2008; 
Cheng et al., 2009) and to inhibit key inflammatory mediators such as TNF and IL1-β 
(Wang et al., 2005).  
 
In the present study, we did not find that repeated sinomenine administration (2 /day for 5 
days) reduced acute inflammation in the CAIA mice. This could be due to several factors, 
such as dose, timing of the treatment and models used. In contrast to the CIA model, 
which requires T-cell activation, the CAIA model, by directly injecting antibodies against 
the type II collagen to trigger arthritis, bypasses this step. Thus, the anti-rheumatic effect 
of sinomenine may be related to inhibition of T-cell activation. Administration of 
sinomenine effectively and dose-dependently alleviated the localized and spread 
mechanical hypersensitivity during both phases without producing side effects. 
Furthermore, repeated administration of sinomenine during the peak of inflammation did 
not change the arthritic scores, despite producing marked analgesia. Thus, it is likely that 
the analgesic mechanism of sinomenine is independent from possible anti-inflammatory 
action of the compound.  
 
No tolerance was seen to the analgesic effect of sinomenine following repeated 
administration. Lack of tolerance to the effect of sinomenine was similarly noted in rodent 
models of neuropathic pain (Gao et al., 2014). It has also been shown that long-term 
pretreatment with sinomenine may delay the analgesic tolerance to morphine (Wang et 
al., 2008). Sinomenine is not an opioid and the anti-nociceptive effect of sinomenine in 
neuropathic pain is not mediated by naloxone sensitive opioid receptors (Gao et al., 
2013). However, sinomenine can interact with neuro-immune crosstalk by suppressing 
microglia activation (Qian et al., 2007; Shukla and Sharma, 2011). Since microglial 
activation was found in the spinal cord of CAIA but not control mice (Bas et al., 2012), it 
is possible that downregulation of microglial activities in the spinal cord by sinomenine is 
responsible for the reduction pain-related behavior in the CAIA model.  
 
Sinomenine also produced a range of other pharmacological effects in the central and 
peripheral nervous system and these effects may also be involved in the analgesic 
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mechanisms of this compound. These effects include immunoregulative properties and 
actions on systems such as histamine, proinflammatory cytokines, COX2 dependent 
PGE2, interferon gamma (INF-γ), reactive oxygen species (ROS), nitric oxide (NO), NF-
κB, p38MAPK, metalloproteinases (MMPs) and TNF. Further identification of the effects 
of sinomenine on neuronal and immune systems may shed lights in understanding of the 
mechanisms of analgesia by sinomenine.   
 
5.5. SEX DIFFERENCES IN THE DEVELOPMENT OF ARTHRITIS AND PAIN 
BEHAVIORS IN CAIA MICE 
 
Similar to previous findings (Nandakumar and Holmdahl, 2007; Bas et al., 2012), we 
showed that in the CBA strain of male and female mice, CII antibodies with LPS 
immunization triggered inflammatory responses in the fore- and hind paws. The extent of 
inflammation, as measured by the arthritis scores, is more profound in the forepaw than in 
the hind paw, which has also been observed for the CBA strain of mice previously (Bas et 
al., 2012). CBA mice of both sexes also developed marked mechanical hypersensitivity in 
the fore- and hindpaws following a similar time course as the development of 
inflammation. However, the duration of mechanical hypersensitivity for both sexes was 
markedly longer than that of inflammation. Thus, while the peak of inflammation was 
reached at around day 15 and inflammation subsided after day 30, the mechanical 
hypersensitivity persists up to day 54 which is the cut-off time of observation. Similar 
disparity between inflammation and hypersensitivity has also been observed previously in 
this model in several strains of mice (Bas et al., 2012) and in other models of RA 
(Christianson et al., 2011). In addition to mechanical hypersensitivity detected in fore- 
and hindpaws, we have also observed persistent mechanical hypersensitivity in mice with 
CAIA at the neck and upper back regions. This may be similar to the neck and back pain 
observed in RA patients resulting from arthritis in the spine (Rawlins et al., 1998). 
Moreover, this may also be related to generalized pain conditions, such as nonarticular 
rheumatism (Moreland and Curtis, 2009). Further, it has been reported that in RA patients 
with long disease duration (>5 years) there was an increased sensitivity to pressure both in 
structures overlying the inflamed joint and in non-inflamed tissues (Leffler et al., 2002).  
 
One of the significant differences between human RA and the widely used rodent model 
of collagen-induced arthritis is the direction of sex differences with rodent studies 
showing that the development of arthritis is more prevalent in males (Holmdahl et al., 
1989; Jansson et al., 1994). It has been shown in a recent study that in a strain of 
transgenic mice that lacked all endogenous mouse class II genes and expressed the RA 
susceptibility allele HLA-DRB1*0401, collagen induced arthritis developed 
predominantly in females (Taneja et al., 2007). We observed similar sex differences in 
inbred CBA strain of mice after CAIA with females exhibiting significantly higher 
arthritis scores as well as more severe localized and spread hypersensitivity to mechanical 
stimulation. These results support the notion that CAIA is a clinically relevant mouse 
model to study sex differences in RA and arthritic pain behaviors. The sex difference in 
arthritis score and mechanical hypersensitivity is reduced in OVXd female mice, 
suggesting a possible role for female sex hormones in such sex differences. The 
relationship between sex hormones and pain has been extensively studied and many 
chronic pain conditions have been shown to be influenced by the level of female sex 
hormones, including changes following the menstrual cycle (LeResche et al., 2003; 
Brandes, 2006; Martin and Lipton, 2008) as well as at the menopause (Pamuk and Cakir, 
2005; Greenspan et al., 2007; Cairns and Gazerani, 2009). On the other hand, the 
relationship between female sex hormones and RA appears to be complicated (Jansson 
and Holmdahl, 1998; Whitacre, 2001; Cutolo et al., 2002; Islander et al., 2011). 
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Ovariectomy was performed in mice 20 days after birth in the current study. Our results 
thus suggest that depleting estrogen circulation at an early age can alter the disease 
progression profile in CAIA. Regardless of the possibly diminished bone protection by 
losing estrogen signaling (Imai, 2013; Ohlsson and Vandenput, 2009), OVXd females still 
had less severe CAIA symptoms than females, suggesting that other key events such as 
epigenetic and developmental modifications following ovariectomy may contradict 
estrogen signaling and modulate sex differences in CAIA. In agreement with the present 
results, we have shown previously that blockade of estrogen signaling by genomic 
knockout of estrogen α or β receptor induced alterations in sensory functions that making 
female mice more resistant to inflammatory pain (Li et al., 2009).  
 
5.6. SEX RELATED PHENOTYPIC CHANGES IN DORSAL ROOT GANGLIA 
AND SPINAL CORD IN CAIA MICE  
 
No changes in expression of SP and CGRP in lumbar DRG and spinal cord dorsal horn 
were observed in the inflammatory or post-inflammatory phase in mice after CAIA, nor 
did we observed sex difference in the expression of SP and CGRP . These results suggest 
that these two peptides are not prime mediators of CAIA induced hypersensitivity and its 
sex differences.  
 
In contrast, the neuropeptide galanin was significantly upregulated in the DRG seen both 
at the mRNA level as well as at the protein level studied by immunohistochemistry. 
Interestingly, galanin level also showed significant sex difference with higher level of 
expression in male mice and such sex difference is partially reversed by ovariectomy. The 
role of galanin in pain modulation at the spinal cord level has been extensively studied, 
and it is now generally agreed that spinally applied galanin produces a biphasic dose-
dependent effect on pain sensitivity through activation of inhibitory galanin receptor 1 or 
excitatory galanin receptor 2 respectively (Xu et al., 2008, 2010). Endogenous galanin has 
primarily an inhibitory (Xu et al., 2008), particularly after peripheral nerve injury when 
the synthesis of galanin is increased in sensory neurons and such increase is correlated to 
the suppression of mechanical hypersensitivity (Hökfelt et al., 1994; Shi et al., 1999). 
This notion has been confirmed in transgenic mice that overexpressing galanin in the 
DRG after sciatic nerve axotomy. Phenotypic analysis revealed markedly attenuated 
allodynia when galanin was overexpressed and an increase in allodynia following galanin 
suppression (Pope et al., 2010). Our current results suggest that galanin may also be 
involved in the modulation of pain sensitivity in CAIA, where an increased level of 
galanin expression in DRG, in response to the systemic inflammation, may help to 
counteract the increase in pain response. Furthermore, the level of galanin was 
significantly higher in male mice than in females after CAIA, correlating with reduced 
pain response in male mice. Interestingly, galanin upon release in the periphery including 
joints may also have anti-inflammatory functions (Lang and Kofler, 2011). Hence, sex-
dependent differential regulation of galanin in the DRG may partially explain sex 
difference in the development of inflammation and pain in the CAIA model in CBA mice 
and it may be suggested that drugs that activate galanin receptor 1 are analgesic in pain 
associated with RA in female patients. Galanin may also be involved in neuronal immune 
interaction counterregulating acute phase inflammation and suppressing excessive 
inflammatory cytokines (TNF- and IL-1) through galanin receptor 2 (Lang and Kofler, 
2011) in addition to its direct effect on pain suppression via galanin receptor 1 (Hao et al., 
1999).  To what extent such effect of galanin is involved in the sex differences in joint 
inflammation in the CAIA model remains to be determined. The underlying mechanisms 
of the sex-dependent differential regulation of galanin in sensory neurons in CAIA mice 
are unclear. Early studies have demonstrated that the galanin gene in some tissues is 
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sensitive to physiological levels of estrogen (Vrontakis et al., 1987; Kaplan et al., 1988). 
However, no sex difference in the level of galanin is seen in normal DRG. Whether or not 
conditions such as RA could change the sensitivity of tissues towards estrogen remains to 
be determined. 
 
Spinal glial activation was seen in both phases of CAIA (Bas et al., 2012), indicating that 
sensitized spinal glial cells may lead to the enhancement of excitatory synaptic 
transmission (Ji et al., 2013). In addition, similar to early findings with CAIA and K/BxN 
serum transfer arthritis models (Christianson et al., 2011; Bas et al., 2012), astrocyte 
activation in the dorsal horn of spinal cord was seen in the post-inflammatory phase of 
CAIA as a secondary event to microglia activation, which may contribute to the 
maintenance of mechanical pain (Spataro et al., 2004). In DRG, Iba-1 positive cells share 
the properties of macrophages since they are usually colocalized with CD68. It has been 
previously suggested that activated macrophages may be involved in peripheral 
sensitization in inflammatory and neuropathic pain models (Dubový et al., 2007; Ji et al., 
2013). In the present study, we found that Iba-1 expression was up-regulated in the DRG 
in mice following CAIA. Furthermore, the number of Iba-1 positive cells was 
significantly higher in female than in male DRGs. This would indicate that macrophage 
activation in the DRG may also be involved in hypersensitivity and its sex differences 
following CAIA. Macrophages infiltration and activation can be triggered by local 
inflammatory events via toll-like receptor 4, NFκB, TNF or IL-1β signaling (Ji et al., 
2013). It is also interesting to note that galanin, as well as ATF-3 can act as the anti-
inflammatory regulators (Gilchrist et al., 2006; Thompson et al., 2009; Pope et al., 2010; 
Lang and Kofler, 2011). Hence, the sex dependent changes in the DRG expression of 
galanin, ATF-3 and Iba-1 after CAIA may be related to each other and play an important 
role in CAIA induced pain. 
 
In my hypothesis illustrated in Fig. 3, I propose that genomic, hormonal and 
developmental factors together influenced the development of sex difference in CAIA 
CBA mice, with females having more pronounced acute inflammation and chronic 
mechanical allodynia. CAIA induces upregulation of galanin and ATF-3 in DRG neurons 
and Iba-1 in macrophage-liked cells. These markers are affected by estrogen signaling 
(male > female for ATF-3 and galanin, male < female for Iba-1). In peripheral tissue, 
ATF-3 is generally believed to induce anti-inflammatory effects. Its mechanism is unclear, 
however, and may be involved in the modulation of neuronal releases of ATP and 
cytokines which may further inhibit toll-like receptor signaling and NFκB activation in 
macrophage-like cells surrounding these neurons. It is known that increased local 
expression of galanin can induce extracellular levels of TNF and IL-1β in DRG (via 
galanin receptor 2), and at the spinal cord level, galanin has an analgesic efficacy 
mediated by GalR1. Taking together, induction of ATF-3 and galanin in DRG following 
CAIA may have suppressive effect on macrophage activation (stained by Iba-1), and 
result in lower peripheral sensitization in males than females.    
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Fig. 3 A schematic illustration of hypothesis of sex related neuro-immune interaction in 
DRG and spinal cord in CBA mice with CAIA. 
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6. CONCLUSIONS 
 
1. Quantitative testing of responsiveness to cold using a Peltier thermode increases 
the detecting cold allodynia and could be used as a valuable tool in studies of the 
mechanisms and treatment of cold allodynia in neuropathic pain. 
 
2. Sinomenine produced anti-nociceptive and analgesic effects in a broad spectrum 
of acute and chronic pain models in rats and mice at doses that did not produce 
observable side effects.  
 
3. The anti-allodynic effect of sinomenine upon repeated chronic administration did 
not lead to tolerance, but rather enhanced its effect, in two rodent models of 
neuropathic pain and in a mouse model of arthritis. This leads to a persistent, but 
reversible, analgesia with no observable side effects. The results from this thesis 
may suggest potential clinical application of sinomenine as a novel analgesic in 
treating chronic neuropathic and arthritic pain. 
 
4. After the induction of CAIA there is a significant sex difference in the level of 
joint inflammation and in associated mechanical hypersensitivity in the CBA 
mouse strain. This is similar to the clinical situation with females having more 
profound arthritis and pain. Further, we showed that such sex differences are 
correlated with the alteration of neuronal expressions of galanin and ATF-3, and 
the macrophage marker Iba-1 in DRG.  
 
5. Our findings suggest that the CAIA model in certain mice strain may be a 
clinically relevant model for studying the mechanisms of sex difference in arthritis 
and arthritis-induced pain which may involve neuro-immune crosstalk. 
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